Overview
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a stabilized analogue of tuftsin, an endogenous tetrapeptide with immunomodulatory properties. Selank has been approved in Russia as an anxiolytic and nootropic drug (brand name Selank).
---
Mechanism of Action
Selank's mechanism is multifaceted and not fully elucidated, but key pathways include:
GABAergic modulation: Research has demonstrated that Selank modulates GABA-A receptor activity, similar to benzodiazepines but through a different binding site. This contributes to its anxiolytic effects without the sedation or dependence associated with classical benzodiazepines.
Serotonin system: Studies have shown that Selank increases serotonin metabolism in the brain, particularly in the hippocampus and frontal cortex.
BDNF upregulation: Selank has been shown to increase brain-derived neurotrophic factor (BDNF) expression, which supports neuroplasticity and cognitive function.
Enkephalin metabolism: Selank inhibits enkephalinase, the enzyme that degrades endogenous enkephalins (endorphin-like peptides), leading to increased enkephalin levels and reduced anxiety.
Immune modulation: As a tuftsin analogue, Selank retains immunomodulatory properties, including activation of macrophages and NK cells.
---
Anxiolytic Research
Comparison with benzodiazepines: Clinical trials in Russia compared Selank to phenazepam (a potent benzodiazepine) in generalized anxiety disorder. Selank demonstrated comparable anxiolytic efficacy with a superior side effect profile — specifically, no sedation, no cognitive impairment, and no dependence potential.
Mechanism vs. benzodiazepines: Unlike benzodiazepines that act as positive allosteric modulators at the GABA-A benzodiazepine binding site, Selank appears to act through a distinct mechanism, explaining its lack of tolerance and dependence.
---
Nootropic Research
Memory and learning: Animal studies have demonstrated that Selank improves performance on spatial memory tasks (Morris water maze) and associative learning paradigms.
Stress-induced cognitive impairment: Research has shown that Selank prevents stress-induced impairment of memory consolidation, suggesting neuroprotective effects under stress conditions.
BDNF and neuroplasticity: The BDNF-upregulating effects of Selank provide a mechanistic basis for its nootropic properties, as BDNF is critical for long-term potentiation (LTP) and memory formation.
---
Selank vs. Semax
| Parameter | Selank | Semax | |-----------|--------|-------| | Primary effect | Anxiolytic, anti-stress | Cognitive enhancement, neuroprotection | | BDNF effect | Moderate upregulation | Strong upregulation | | Anxiety | Reduces | Neutral to mild reduction | | Stimulant effect | None | Mild | | Approval | Russia (anxiolytic) | Russia (nootropic) |
---
Clinical Trials
Selank has been evaluated in several Russian clinical trials:
- Generalized anxiety disorder: Demonstrated efficacy comparable to phenazepam with superior tolerability
- Neurasthenia: Improved fatigue, cognitive function, and emotional stability
- Alcohol withdrawal: Showed promise in reducing anxiety and improving sleep during alcohol withdrawal
---
Summary
Selank represents a unique class of anxiolytic peptide with a mechanism distinct from classical benzodiazepines. Its combination of anxiolytic, nootropic, and immunomodulatory effects, along with an absence of sedation or dependence potential, makes it a valuable research tool for studying anxiety neurobiology and cognitive function.
See Also: Semax Deep Dive: Cognitive Enhancement and Neuroprotection Research | Peptide Research Glossary: Key Terms and Definitions
Shop Research Grade: View Selank Research Grade →